Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab

NCT04887831 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

92

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor no longer pursuing trilaciclib for the indication.

Conditions

Urothelial Carcinoma
Bladder Cancer
Myelosuppression Adult
Chemotherapy-induced Neutropenia
Metastatic Bladder Cancer

Interventions

DRUG: Trilaciclib
DRUG: Gemcitabine
DRUG: Cisplatin
DRUG: Carboplatin
DRUG: Avelumab

Sponsor

G1 Therapeutics, Inc.